IL1B and COVID-19: TCs have shown great potential for the management of COVID-19 through inhibition of SARS-CoV-2–induced hyperinflammation and cytokine storm, since TCs downregulate the production of inflammatory cytokines, including interleukins (IL-6, IL-33, and IL-1β) and tumor necrosis factor (TNF)-α.